{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:56:35Z","timestamp":1696622195367},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,10,30]],"date-time":"2011-10-30T00:00:00Z","timestamp":1319932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0099-2","type":"journal-article","created":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T09:33:48Z","timestamp":1319880828000},"page":"2088-2094","source":"Crossref","is-referenced-by-count":6,"title":["The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience"],"prefix":"10.1007","volume":"29","author":[{"given":"Bin-Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Chun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arati","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,30]]},"reference":[{"key":"99_CR1","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505\u201315.","journal-title":"Blood"},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","volume":"106","author":"J Hu","year":"2009","unstructured":"Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","volume":"41","author":"J Bernard","year":"1973","unstructured":"Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41:489\u201396.","journal-title":"Blood"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.V73.5.1116.1116","volume":"73","author":"I Cunningham","year":"1989","unstructured":"Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116\u201322.","journal-title":"Blood"},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1097-0142(19880101)61:1<7::AID-CNCR2820610103>3.0.CO;2-6","volume":"61","author":"MA Sanz","year":"1988","unstructured":"Sanz MA, Jarque I, Mart\u00edn G, Lorenzo I, Mart\u00ednez J, Rafecas J, et al. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer. 1988;61:7\u201313.","journal-title":"Cancer"},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","volume":"113","author":"MA Sanz","year":"2009","unstructured":"Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113:1875\u201391.","journal-title":"Blood"},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2010.32.1067","volume":"29","author":"MA Sanz","year":"2011","unstructured":"Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29:495\u2013503.","journal-title":"J Clin Oncol"},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","volume":"100","author":"MS Tallman","year":"2002","unstructured":"Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298\u2013302.","journal-title":"Blood"},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2009.183","volume":"23","author":"E Lengfelder","year":"2009","unstructured":"Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23:2248\u201358.","journal-title":"Leukemia"},{"key":"99_CR10","doi-asserted-by":"crossref","unstructured":"Stone RM, O\u2019Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98\u2013117.","DOI":"10.1182\/asheducation-2004.1.98"},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/sj.leu.2403009","volume":"17","author":"RF Schlenk","year":"2003","unstructured":"Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521\u20138.","journal-title":"Leukemia"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/10428190600627055","volume":"47","author":"EM Fagundes","year":"2006","unstructured":"Fagundes EM, Rocha V, Gl\u00f3ria AB, Clementino NC, Quint\u00e3o JS, Guimar\u00e3es JP, et al. De novo acute myeloid leukemia in adults younger than 60\u00a0years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006;47:1557\u201364.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"99_CR13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2004.10.009","volume":"29","author":"A B\u00f6hm","year":"2005","unstructured":"B\u00f6hm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Kn\u00f6bl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;29(6):609\u201315.","journal-title":"Leuk Res"},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/10428190601136163","volume":"48","author":"A Zayed","year":"2007","unstructured":"Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I, et al. Acute promyelocytic leukemia: a novel PML\/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma. 2007;48:489\u201396.","journal-title":"Leuk Lymphoma"},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.beha.2008.09.002","volume":"21","author":"MS Tallman","year":"2008","unstructured":"Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol. 2008;21:659\u201366.","journal-title":"Best Pract Res Clin Haematol"},{"key":"99_CR16","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852\u201360.","journal-title":"J Clin Oncol"},{"key":"99_CR17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2002.03409.x","volume":"117","author":"WY Au","year":"2002","unstructured":"Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol. 2002;117:130\u20132.","journal-title":"Br J Haematol"},{"key":"99_CR18","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/sj.leu.2403050","volume":"17","author":"A Grigg","year":"2003","unstructured":"Grigg A, Kimber R, Szer J. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia. 2003;17:1916\u20137.","journal-title":"Leukemia"},{"key":"99_CR19","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354\u201360.","journal-title":"Blood"},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1532\/IJH97.05044","volume":"82","author":"K Shigeno","year":"2005","unstructured":"Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol. 2005;82:224\u20139.","journal-title":"Int J Hematol"},{"key":"99_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3816\/CLML.2010.s.026","volume":"10","author":"A Ranganathan","year":"2010","unstructured":"Ranganathan A, Powell BL. Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10:135\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3816\/CLML.2010.s.025","volume":"10","author":"MA Sanz","year":"2010","unstructured":"Sanz MA, Montesinos P. Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10:130\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","volume":"116","author":"BL Powell","year":"2010","unstructured":"Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751\u20137.","journal-title":"Blood"},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-007-0269-7","volume":"86","author":"MM van den Heuvel-Eibrink","year":"2007","unstructured":"van den Heuvel-Eibrink MM, van der Holt B, Marry M, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329\u201337.","journal-title":"Ann Hematol"},{"key":"99_CR26","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","volume":"27","author":"F Mandelli","year":"2009","unstructured":"Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397\u2013403.","journal-title":"J Clin Oncol"},{"key":"99_CR27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","volume":"103","author":"MA Sanz","year":"2004","unstructured":"Sanz MA, Mart\u00edn G, Gonz\u00e1lez M, Le\u00f3n A, Ray\u00f3n C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with alltrans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237\u201343.","journal-title":"Blood"},{"key":"99_CR28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2007-07-099978","volume":"111","author":"L Ad\u00e8s","year":"2008","unstructured":"Ad\u00e8s L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111:1078\u201384.","journal-title":"Blood"},{"key":"99_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2006.11.002","volume":"20","author":"MS Tallman","year":"2007","unstructured":"Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20:57\u201365.","journal-title":"Best Pract Res Clin Haematol"},{"key":"99_CR30","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.0400053101","volume":"101","author":"ZX Shen","year":"2004","unstructured":"Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328\u201335.","journal-title":"Proc Natl Acad Sci USA"},{"key":"99_CR31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12185-010-0553-5","volume":"91","author":"Y Chen","year":"2010","unstructured":"Chen Y, Gu L, Zhou C, Wu X, Gao J, Li Q, et al. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival. Int J Hematol. 2010;91:708\u201310.","journal-title":"Int J Hematol"},{"key":"99_CR32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2009.25.5158","volume":"28","author":"SD Gore","year":"2010","unstructured":"Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28:1047\u201353.","journal-title":"J Clin Oncol"},{"key":"99_CR33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/pbc.21835","volume":"52","author":"LY Ramirez","year":"2009","unstructured":"Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E. Potential chemotherapy side effects: what do oncologists tell parents? Pediatr Blood Cancer. 2009;52:497\u2013502.","journal-title":"Pediatr Blood Cancer"},{"key":"99_CR34","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","volume":"21","author":"JT Barbey","year":"2003","unstructured":"Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609\u201315.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0099-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0099-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T18:33:01Z","timestamp":1593196381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0099-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,30]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0099-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,30]]}}}